{"id":"https://openalex.org/W2979401211","doi":"https://doi.org/10.1182/blood.v126.23.1893.1893","title":"Manufacturing an Enhanced CAR T Cell Product By Inhibition of the PI3K/Akt Pathway During T Cell Expansion Results in Improved In Vivo Efficacy of Anti-BCMA CAR T Cells","display_name":"Manufacturing an Enhanced CAR T Cell Product By Inhibition of the PI3K/Akt Pathway During T Cell Expansion Results in Improved In Vivo Efficacy of Anti-BCMA CAR T Cells","publication_year":2015,"publication_date":"2015-12-03","ids":{"openalex":"https://openalex.org/W2979401211","doi":"https://doi.org/10.1182/blood.v126.23.1893.1893","mag":"2979401211"},"language":"en","primary_location":{"id":"doi:10.1182/blood.v126.23.1893.1893","doi":"https://doi.org/10.1182/blood.v126.23.1893.1893","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v126.23.1893.1893","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5110747776","display_name":"Molly R. Perkins","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210155646","display_name":"Bluebird Bio (United States)","ror":"https://ror.org/04vaq9436","country_code":"US","type":"company","lineage":["https://openalex.org/I4210155646"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Molly R. Perkins","raw_affiliation_strings":["bluebird bio, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"bluebird bio, Cambridge, MA","institution_ids":["https://openalex.org/I4210155646"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087524629","display_name":"Shannon M. Grande","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210155646","display_name":"Bluebird Bio (United States)","ror":"https://ror.org/04vaq9436","country_code":"US","type":"company","lineage":["https://openalex.org/I4210155646"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Shannon Grande","raw_affiliation_strings":["bluebird bio, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"bluebird bio, Cambridge, MA","institution_ids":["https://openalex.org/I4210155646"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080592738","display_name":"Amanda Hamel","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210155646","display_name":"Bluebird Bio (United States)","ror":"https://ror.org/04vaq9436","country_code":"US","type":"company","lineage":["https://openalex.org/I4210155646"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Amanda Hamel","raw_affiliation_strings":["bluebird bio, Inc, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"bluebird bio, Inc, Cambridge, MA","institution_ids":["https://openalex.org/I4210155646"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009657522","display_name":"Holly M. Horton","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210155646","display_name":"Bluebird Bio (United States)","ror":"https://ror.org/04vaq9436","country_code":"US","type":"company","lineage":["https://openalex.org/I4210155646"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Holly M. Horton","raw_affiliation_strings":["bluebird bio, Inc, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"bluebird bio, Inc, Cambridge, MA","institution_ids":["https://openalex.org/I4210155646"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050285439","display_name":"Tracy E. Garrett","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210155646","display_name":"Bluebird Bio (United States)","ror":"https://ror.org/04vaq9436","country_code":"US","type":"company","lineage":["https://openalex.org/I4210155646"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Tracy E. Garrett","raw_affiliation_strings":["bluebird bio, Inc, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"bluebird bio, Inc, Cambridge, MA","institution_ids":["https://openalex.org/I4210155646"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054107816","display_name":"Sara M. Miller","orcid":"https://orcid.org/0000-0002-5113-6675","observed_orcids":["https://orcid.org/0000-0002-5113-6675"]},"institutions":[{"id":"https://openalex.org/I4210155646","display_name":"Bluebird Bio (United States)","ror":"https://ror.org/04vaq9436","country_code":"US","type":"company","lineage":["https://openalex.org/I4210155646"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sara M. Miller","raw_affiliation_strings":["bluebird bio, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"bluebird bio, Cambridge, MA","institution_ids":["https://openalex.org/I4210155646"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002318821","display_name":"Howard J. Latimer","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210155646","display_name":"Bluebird Bio (United States)","ror":"https://ror.org/04vaq9436","country_code":"US","type":"company","lineage":["https://openalex.org/I4210155646"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Howard J. Latimer","raw_affiliation_strings":["bluebird bio, Inc, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"bluebird bio, Inc, Cambridge, MA","institution_ids":["https://openalex.org/I4210155646"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021326339","display_name":"Christopher J. Horvath","orcid":"https://orcid.org/0009-0003-0996-9176","observed_orcids":["https://orcid.org/0009-0003-0996-9176"]},"institutions":[{"id":"https://openalex.org/I4210155646","display_name":"Bluebird Bio (United States)","ror":"https://ror.org/04vaq9436","country_code":"US","type":"company","lineage":["https://openalex.org/I4210155646"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Christopher J. Horvath","raw_affiliation_strings":["bluebird bio, Inc, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"bluebird bio, Inc, Cambridge, MA","institution_ids":["https://openalex.org/I4210155646"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040489316","display_name":"Michael Kuczewski","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210155646","display_name":"Bluebird Bio (United States)","ror":"https://ror.org/04vaq9436","country_code":"US","type":"company","lineage":["https://openalex.org/I4210155646"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael Kuczewski","raw_affiliation_strings":["bluebird bio, Inc, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"bluebird bio, Inc, Cambridge, MA","institution_ids":["https://openalex.org/I4210155646"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074192094","display_name":"Kevin M. Friedman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210155646","display_name":"Bluebird Bio (United States)","ror":"https://ror.org/04vaq9436","country_code":"US","type":"company","lineage":["https://openalex.org/I4210155646"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kevin M. Friedman","raw_affiliation_strings":["bluebird bio, Inc, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"bluebird bio, Inc, Cambridge, MA","institution_ids":["https://openalex.org/I4210155646"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5103198733","display_name":"Richard A. Morgan","orcid":"https://orcid.org/0000-0003-0689-0916","observed_orcids":["https://orcid.org/0000-0003-0689-0916"]},"institutions":[{"id":"https://openalex.org/I4210155646","display_name":"Bluebird Bio (United States)","ror":"https://ror.org/04vaq9436","country_code":"US","type":"company","lineage":["https://openalex.org/I4210155646"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Richard A. Morgan","raw_affiliation_strings":["bluebird bio, Inc, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"bluebird bio, Inc, Cambridge, MA","institution_ids":["https://openalex.org/I4210155646"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4210155646"],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":0.1457,"has_fulltext":false,"cited_by_count":27,"citation_normalized_percentile":{"value":0.60724139,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":98},"biblio":{"volume":"126","issue":"23","first_page":"1893","last_page":"1893"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11491","display_name":"CAR-T cell therapy research","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11491","display_name":"CAR-T cell therapy research","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10031","display_name":"T-cell and B-cell Immunology","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/chimeric-antigen-receptor-t-cells","display_name":"chimeric antigen receptor T cells","score":0.7429999709129333},{"id":"https://openalex.org/keywords/b-cell-maturation-antigen","display_name":"BCMA","score":0.847000002861023},{"id":"https://openalex.org/keywords/t-cell-expansion","display_name":"T cell expansion","score":0.7279999852180481},{"id":"https://openalex.org/keywords/interleukin-2","display_name":"interleukin-2","score":0.8069999814033508},{"id":"https://openalex.org/keywords/burkitt-lymphoma","display_name":"Burkitt lymphoma","score":0.921999990940094},{"id":"https://openalex.org/keywords/multiple-myeloma","display_name":"multiple myeloma","score":0.9990000128746033},{"id":"https://openalex.org/keywords/relapsed-refractory-disease","display_name":"relapsed/refractory disease","score":0.7239999771118164},{"id":"https://openalex.org/keywords/tumor-regression","display_name":"tumor regression","score":0.5230000019073486},{"id":"https://openalex.org/keywords/car-t-cell-manufacturing","display_name":"CAR T cell manufacturing","score":0.6230000257492065},{"id":"https://openalex.org/keywords/daudi-cells","display_name":"Daudi cells","score":0.5640000104904175},{"id":"https://openalex.org/keywords/rpmi-8226-cells","display_name":"RPMI 8226 cells","score":0.9259999990463257},{"id":"https://openalex.org/keywords/nsg-mice","display_name":"NSG mice","score":0.5590000152587891}],"concepts":[{"id":"https://openalex.org/C3875195","wikidata":"https://www.wikidata.org/wiki/Q5099363","display_name":"Chimeric antigen receptor","level":4,"score":0.7690053582191467},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5417559146881104},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.5313770174980164},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.5010454654693604},{"id":"https://openalex.org/C2778957590","wikidata":"https://www.wikidata.org/wiki/Q798033","display_name":"CD19","level":3,"score":0.48280060291290283},{"id":"https://openalex.org/C81885089","wikidata":"https://www.wikidata.org/wiki/Q189082","display_name":"Cell culture","level":2,"score":0.464647501707077},{"id":"https://openalex.org/C2776090121","wikidata":"https://www.wikidata.org/wiki/Q193529","display_name":"T cell","level":3,"score":0.447050541639328},{"id":"https://openalex.org/C148125776","wikidata":"https://www.wikidata.org/wiki/Q1622348","display_name":"CD28","level":4,"score":0.4462604522705078},{"id":"https://openalex.org/C26291073","wikidata":"https://www.wikidata.org/wiki/Q310484","display_name":"Ex vivo","level":3,"score":0.43798619508743286},{"id":"https://openalex.org/C86554907","wikidata":"https://www.wikidata.org/wiki/Q285613","display_name":"PI3K/AKT/mTOR pathway","level":3,"score":0.4359845519065857},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.39392590522766113},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.3746423125267029},{"id":"https://openalex.org/C147483822","wikidata":"https://www.wikidata.org/wiki/Q103537","display_name":"Antigen","level":2,"score":0.35644447803497314},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.33967679738998413},{"id":"https://openalex.org/C95444343","wikidata":"https://www.wikidata.org/wiki/Q7141","display_name":"Cell biology","level":1,"score":0.2303062081336975},{"id":"https://openalex.org/C62478195","wikidata":"https://www.wikidata.org/wiki/Q828130","display_name":"Signal transduction","level":2,"score":0.1100512146949768},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.09299296140670776},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood.v126.23.1893.1893","doi":"https://doi.org/10.1182/blood.v126.23.1893.1893","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v126.23.1893.1893","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9922999739646912,"id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2488383025","https://openalex.org/W3099381423","https://openalex.org/W3022909995","https://openalex.org/W2592588416","https://openalex.org/W2564643751","https://openalex.org/W4401132162","https://openalex.org/W4388688099","https://openalex.org/W7020940455","https://openalex.org/W2937680065","https://openalex.org/W4417007538"],"abstract_inverted_index":{"Abstract":[0],"Patients":[1],"treated":[2,233,329,451],"with":[3,69,165,175,217,234,330,336,368,432,452,458,480,490,500,540],"chimeric":[4],"antigen":[5,158],"receptor":[6],"(CAR)":[7],"T":[8,26,50,63,74,84,92,106,138,151,239,283,308,333,352,387,393,418,455,477,497,510,526,548,566],"cells":[9,27,51,85,107,139,152,222,240,284,309,334,353,388,434,456,478,498,511],"targeting":[10],"CD19":[11],"for":[12,39,90,128,551],"B":[13,155],"cell":[14,75,156,419,527,549,567],"malignancies":[15],"have":[16,79],"experienced":[17,342],"rapid":[18],"and":[19,57,99,110,177,198,223,270,294,313,341,373],"durable":[20],"tumor":[21,229,258,289,319,345,406,425,441,465],"regressions.":[22],"Manufacture":[23],"of":[24,48,62,105,136,168,181,193,203,276,359,384,409,474,507,522,534,564],"CAR":[25,54,73,137,150,282,307,332,351,386,417,454,476,496,547],"is":[28],"challenged":[29],"by":[30,116],"the":[31,126,133,172,208,299,337,410,436,469,491,513,562],"necessity":[32],"to":[33,52,58,87,101,119,131,143,154,171,225,262,298,317,439,463,485],"produce":[34],"a":[35,227,357,380,523,544],"unique":[36],"drug":[37],"product":[38,515,550],"each":[40],"patient.":[41],"Each":[42],"treatment":[43,403],"requires":[44],"ex":[45,66,537],"vivo":[46,67,185,472,538],"culture":[47,68,129,164,413],"patient":[49],"facilitate":[53],"gene":[55],"transfer":[56],"achieve":[59],"therapeutic":[60,91,121,134,493],"amounts":[61],"cells.":[64],"Paradoxically,":[65],"IL-2":[70,163,279,541],"also":[71,113,315],"decreases":[72],"activity.":[76,122,494],"Some":[77],"investigators":[78,118],"proposed":[80],"isolating":[81],"central":[82],"memory":[83],"(thought":[86],"be":[88,559],"enriched":[89],"cells),":[93],"yet":[94],"isolation":[95],"techniques":[96],"are":[97],"cumbersome":[98],"costly":[100],"scale":[102],"commercially.":[103],"Culture":[104],"in":[108,179,184,189,268,311,356,411,471,512,561],"IL-7":[109,176,312],"IL-15":[111,178,314],"has":[112],"been":[114,450],"shown":[115],"several":[117],"improve":[120,132],"Here":[123],"we":[124,483],"explored":[125],"potential":[127,135],"modifications":[130],"without":[140],"adding":[141],"complexity":[142],"manufacturing.":[144],"We":[145,443],"tested":[146],"this":[147,247,274,400,555],"hypothesis":[148],"using":[149,161],"specific":[153],"maturation":[157],"(BCMA)":[159],"manufactured":[160],"standard":[162],"an":[166,504],"inhibitor":[167,339],"PI3K":[169,338,459,481,501,535],"added":[170],"media,":[173],"or":[174],"place":[180],"IL-2.":[182],"The":[183,348],"activity":[186],"was":[187,261],"studied":[188],"NSG":[190,211,362],"mouse":[191],"models":[192],"human":[194],"Burkitt's":[195],"lymphoma":[196,209],"(Daudi),":[197],"multiple":[199,360],"myeloma":[200],"(RPMI-8226),":[201],"both":[202],"which":[204],"express":[205],"BCMA.":[206],"In":[207,273,324,399],"model,":[210,401],"mice":[212,253,296,363,378],"were":[213,354,364,429,461],"injected":[214,365],"intravenously":[215],"(IV)":[216],"2":[218],"x":[219,236,390],"106":[220,237],"Daudi":[221,257],"allowed":[224],"accumulate":[226],"large":[228],"burden":[230],"before":[231],"being":[232],"4":[235],"CAR+":[238,392],"on":[241,288,435],"day":[242],"18":[243],"post-tumor":[244],"injection.":[245],"At":[246],"late":[248,264],"time":[249],"point":[250],"post":[251],"implantation,":[252],"had":[254,285,449],"highly":[255],"disseminated":[256],"(our":[259],"goal":[260],"model":[263,275,358,440],"stage":[265],"disease":[266],"observed":[267],"relapsed":[269],"refractory":[271],"lymphoma).":[272],"advanced":[277],"disease,":[278],"cultured":[280,335,395,457,479,499],"anti-BCMA":[281,331,350,385,453,475,546],"no":[286],"effect":[287],"growth":[290,320],"(p":[291,321,516],"=":[292,322],"0.22)":[293],"all":[295,327,402],"succumbed":[297],"tumors":[300],"within":[301],"two":[302,421],"weeks":[303,422],"after":[304,423],"treatment.":[305],"Anti-BCMA":[306,495],"grown":[310],"failed":[316],"control":[318],"0.23).":[323],"sharp":[325],"contrast,":[326],"animals":[328,428,447],"survived":[340],"complete":[343],"long-term":[344],"regression":[346],"(p=0.003).":[347],"same":[349],"used":[355,560],"myeloma.":[361],"subcutaneously":[366],"(SC)":[367],"107":[369],"RPMI-8226":[370,433],"MM":[371],"cells,":[372],"at":[374],"22":[375],"days":[376],"post-implantation":[377],"received":[379],"single":[381],"IV":[382],"administration":[383],"(4":[389],"105":[391],"cells/mouse)":[394],"under":[396],"various":[397],"conditions.":[398,414],"groups":[404],"demonstrated":[405],"regression,":[407],"regardless":[408],"vitro":[412],"To":[415],"evaluate":[416],"durability,":[420],"initial":[424],"clearance,":[426],"surviving":[427],"then":[430],"re-challenged":[431],"opposite":[437],"flank":[438],"relapse.":[442],"found":[444],"that":[445,448,532],"only":[446],"inhibition":[460,502,533],"immune":[462],"subsequent":[464],"challenge":[466],"(p=0.005).":[467],"Given":[468],"superior":[470,545],"efficacy":[473],"inhibition,":[482],"sought":[484],"identify":[486],"phenotypic":[487],"characteristics":[488],"associated":[489],"improved":[492,520],"contained":[503],"increased":[505],"frequency":[506],"CD62L+":[508],"CD8":[509,525],"final":[514],"<":[517],"0.001)":[518],"suggesting":[519],"expansion":[521,539],"distinct":[524],"subset.":[528],"These":[529],"data":[530],"suggest":[531],"during":[536],"may":[542],"generate":[543],"clinical":[552],"use.":[553],"Furthermore,":[554],"approach":[556],"could":[557],"potentially":[558],"manufacture":[563],"other":[565],"therapies.":[568],"Disclosures":[569],"Perkins:":[570],"bluebird":[571],"bio:":[572,577,582,587,592,597,602,607,612,617,622],"Employment,":[573,578,583,588,593,598,603,608,613,618,623],"Equity":[574,579,584,589,594,599,604,609,614,619,624],"Ownership.":[575,580,585,590,595,600,605,610,615,620,625],"Grande:bluebird":[576],"Hamel:bluebird":[581],"Horton:bluebird":[586],"Garrett:bluebird":[591],"Miller:bluebird":[596],"Latimer:bluebird":[601],"Horvath:bluebird":[606],"Kuczewski:bluebird":[611],"Friedman:bluebird":[616],"Morgan:bluebird":[621]},"counts_by_year":[{"year":2025,"cited_by_count":5},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":4},{"year":2022,"cited_by_count":6},{"year":2021,"cited_by_count":5},{"year":2020,"cited_by_count":4},{"year":2019,"cited_by_count":1},{"year":2017,"cited_by_count":1}],"updated_date":"2026-10-02T10:15:12.560889","created_date":"2019-10-18T00:00:00"}